Leeds's St James's University Hospital manages HIV and Hepatitis B patients across West Yorkshire including patients from Leeds's large South Asian and Eastern European communities. Tavin TDF 300mg provides Leeds patients requiring private antiviral supply — for both HIV treatment and Hepatitis B management — with proven dual antiviral efficacy at significantly reduced cost.
Unnati Pharmax ships to Leeds and across Yorkshire. Visit unnatipharmax.com or WhatsApp +91 82650 41513 or email Unnatipharmax@gmail.com.
Unnati Pharmax ships to Leeds and across Yorkshire. Visit unnatipharmax.com or WhatsApp +91 82650 41513 or email Unnatipharmax@gmail.com.
FAQ 1: How does Tenofovir (Tavin) work against both HIV and Hepatitis B simultaneously?Tenofovir Disoproxil Fumarate (Tavin) works by inhibiting viral polymerase enzymes — specifically HIV reverse transcriptase and HBV DNA polymerase. Both HIV and HBV are DNA polymerase-dependent viruses that use these enzymes to replicate their genetic material inside host cells. Tenofovir is a nucleotide analogue that is incorporated into the growing viral DNA chain, acting as a chain terminator that prevents further replication. The structural similarity between HIV reverse transcriptase and HBV DNA polymerase means Tenofovir inhibits both enzymes effectively — which is why it is uniquely positioned as a dual-indication antiviral, treating both infections simultaneously when a patient is co-infected. FAQ 2: What kidney monitoring is required for long-term Tavin users?TDF (Tavin) can affect proximal tubular function in the kidney in a minority of patients, making regular monitoring essential. Standard monitoring protocol includes: eGFR (estimated glomerular filtration rate) and serum creatinine at baseline before starting, then at 3 months, 6 months, and every 6 months thereafter. Urine phosphate and glucose testing are added in some protocols to detect proximal tubular dysfunction early. Leeds HIV and hepatology clinicians also check phosphate levels — low phosphate (hypophosphataemia) is an early marker of tubular dysfunction. If eGFR declines below 50 mL/min or tubular dysfunction is detected, switching to the TAF alternative (Tafsure) is typically recommended, as TAF achieves the same antiviral effect at much lower plasma concentrations with negligible renal impact. FAQ 3: Can Tavin be used in elderly patients with pre-existing kidney disease?TDF (Tavin) requires dose adjustment or substitution in patients with reduced kidney function. For patients with eGFR above 50 mL/min, standard dosing is appropriate with monitoring. For eGFR 30-49 mL/min, dose interval extension to every 48 hours may be needed. For eGFR below 30 mL/min or dialysis patients, TDF is generally avoided in favour of TAF (Tafsure) or alternative antivirals with renal dose adjustment protocols. Leeds's geriatric and hepatology specialists often collaborate when managing older patients with Hepatitis B and concurrent kidney disease — where TAF (Tafsure) is typically preferred over Tavin from the outset given its much safer renal profile in this population. FAQ 4: What bone density changes does Tavin cause and how can they be managed?TDF is associated with modest but measurable reductions in bone mineral density — typically 2-3% at the hip and spine over the first 1-2 years of therapy, after which it stabilises. This occurs because TDF's systemic phosphate-wasting effect reduces the phosphate available for bone mineralisation, and also because TDF elevates parathyroid hormone levels that stimulate bone resorption. For most patients the absolute bone density reduction is clinically modest, but those with pre-existing osteoporosis risk factors — postmenopausal women, smokers, low body weight, steroid users, vitamin D deficiency — require closer monitoring with DEXA scanning. Adequate calcium (1000-1200mg/day) and vitamin D (800-1000 IU/day) supplementation, regular weight-bearing exercise, and smoking cessation all mitigate TDF's bone effects in Leeds patients on long-term therapy. FAQ 5: If I stop Tavin for Hepatitis B, what happens and is it safe?Abrupt discontinuation of TDF (Tavin) in Hepatitis B patients — unlike HIV patients — carries a specific and serious risk of HBV reactivation flare. When TDF is stopped, HBV viral replication rebounds rapidly (sometimes within days to weeks), causing an acute hepatitis flare that can be severe or even life-threatening in patients with pre-existing liver damage. This is called HBV flare or immune reconstitution hepatitis. Stopping Tavin for Hepatitis B should therefore never be done abruptly or without specialist input. If switching to an alternative antiviral, the switch must be done carefully with overlapping therapy. Leeds hepatologists discuss the lifelong nature of HBV treatment with patients — unlike HCV which can be cured, HBV requires indefinite viral suppression in the vast majority of patients to prevent flare and disease progression.